-
1. Nakamura M, Yaku H, Ako J, Arai H, Asai T, Chikamori T, Daida H, Doi K, Fukui T, Ito T, Kadota K, Kobayashi J, Komiya T, Kozuma K, Nakagawa Y, Nakao K, Niinami H, Ohno T, Ozaki Y, Sata M, Takanashi S, Takemura H, Ueno T, Yasuda S, Yokoyama H, Fujita T, Kasai T, Kohsaka S, Kubo T, Manabe S, Matsumoto N, Miyagawa S, Mizuno T, Motomura N, Numata S, Nakajima H, Oda H, Otake H, Otsuka F, Sasaki KI, Shimada K, Shimokawa T, Shinke T, Suzuki T, Takahashi M, Tanaka N, Tsuneyoshi H, Tojo T, Une D, Wakasa S, Yamaguchi K, Akasaka T, Hirayama A, Kimura K, Kimura T, Matsui Y, Miyazaki S, Okamura Y, Ono M, Shiomi H, Tanemoto K; Japanese Circulation Society Joint Working Group. JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. Circ J. 2022 Feb 25;86(3):477-588.
-
2. Yokoyama M, Kamide N, Tojo T, Yamaoka-Tojo M. Cardiovascular Disease Prevention in the COVID-19 Era. Austin J Cardiovasc Dis Atherosclerosis 2021 Apr 8(1) 1042.
-
3. Tojo T, Yamaoka-Tojo M. Anti-inflammatory Effects of Pentraxin 3 in Human Visceral Adipocytes by Reducing Reactive Oxygen Species Production. Cardiol Cardiovasc Med 2021 Mar. 55(2) 213 ? 217.
-
4. Tojo T, Yamaoka-Tojo M. The Plasma Level of B-Type Natriuretic Peptide is a Useful Predictor of Cardiac Events for Out-Clinic Patients with Asymptomatic Heart Failure. Austin J Cardiovasc Dis Atherosclerosis 2021 Mar. 8(1) 1041.
-
5. Tojo T, Yamaoka-Tojo M. Nutrition for Elderly Patients with Cardiovascular Diseases. Austin Journal of Cardiovascular Disease and Atherosclerosis 2021 Mar. 8(1) 1040.
-
6. Tojo T, Yamaoka-Tojo M. Lifestyle Modification-Improving Systemic Athero-Protective Factor, Circulating Pentraxin 3, in High-Risk Patients with Metabolic Syndrome. Cardiol Cardiovasc Med 2021 Mar. 5(2) 201 ? 212.
-
7. Nemoto T, Minami Y, Sato T, Muramatsu Y, Kakizaki R, Hashimoto T, Oikawa J, Fujiyoshi K, MeguroK, Shimohama T, Tojo T, Ako J. Contrast Volume and Decline in Kidney Function in Optical Coherence Tomography-Guided Percutaneous Coronary Intervention. Int Heart J. 2019 Sep 27;60(5):1022-1029.
-
8. Nemoto T, Minami Y, Yamaoka-Tojo M, Sato T, Muramatsu Y, Kakizaki R, Fujiyoshi K, Hashimoto T, Meguro K, Shimohama T, Tojo T, Ako J. Impaired Flow-Mediated Dilation and Severity and Vulnerability of Culprit Plaque in Patients with Coronary Artery Disease. Int Heart J. 2019 May 30;60(3):539-545.
-
9. Fujiyoshi K, Minami Y, Ishida K, Kato A, Muramatsu Y, Sato T, Kakizaki R, Nemoto T, Hashimoto T, Sato N, Meguro K, Shimohama T, Tojo T, Ako J. Incidence, factors, and clinical significance of cholesterol crystals in coronary plaque: An optical coherence tomography study. Atherosclerosis. 2019 Apr; 283:79-84.
-
10. Sato N, Minami Y, Shimohama T, Kameda R, Tojo T, Ako J. Vascular response and intrastent thrombus in the early phase after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: An observational, single-center study. Health Sci Rep. 2018 Dec 5;2(1):e105.
-
11. Hashimoto T, Minami Y, Kakizaki R, Nemoto T, Fujiyoshi K, Meguro K, Shimohama T, Tojo T, Ako J. Achilles tendon thickening is associated with disease severity and plaque vulnerability in patients with coronary artery disease. J Clin Lipidol. 2018 Oct 29. pii: S1933-2874(18)30427-6.
-
12. Hashikata T, Matsushita M, Shindo A, Kakuda N, Tojo T, Ohnishi S, Yamasaki M. Stent Recoil in Overlapping Stent 18 Years After Wiktor Stent Implantation. Int Heart J. 2018 Nov 20. doi: 10.1536/ihj.18-261.
-
13. Katamine M, Minami Y, Yanagisawa T, Meguro K, Shimohama T, Tojo T, Ako J. Unexpected Measurement Error in Optical Coherence Tomography-Guided Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2018 Nov 12;11(21):e179-e180.
-
14. Fujiyoshi K, Yamaoka-Tojo M, Minami Y, Kutsuna T, Obara S, Kakizaki R, Nemoto T, Hashimoto T, Namba S, Shimohama T, Tojo T, Ako J. Endothelial Dysfunction Is Associated with Cognitive Impairment of Elderly Cardiovascular Disease Patients. Int Heart J. 2018 Sep 26;59(5):1034-1040.
-
15. Kakizaki R, Minami Y, Hashikata T, Nemoto T, Hashimoto T, Fujiyoshi K, Meguro K, Shimohama T, Tojo T, Ako J. Impact of underlying plaque type on strut coverage in the early phase after drug-eluting stent implantation. Coron Artery Dis. 2018 Dec;29(8):624-631.
-
16. Fujiyoshi K, Minami Y, Tojo T, Iwase D, Hirata M, Ako J. Lower limb ischemia due to popliteal artery compression by Baker cyst. J Vasc Surg Cases Innov Tech. 2018 Apr 25;4(2):99-101.
-
17. Katsura A, Minami Y, Tojo T, Ako J. Neoatherosclerosis With Napkin Ring Calcification. Circ J. 2018 Jul 25;82(8):2208-2209.
-
18. Hashikata T, Tojo T, Muramatsu Y, Sato T, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, Kitasato L, Hashimoto T, Kameda R, Shimohama T, Yamaoka-Tojo M, Ako J. Lower Level of Low Density Lipoprotein Cholesterol is Associated with a Higher Increase in the Fractional Flow Reserve in Patients with Fixed-dose Rosuvastatin. J Atheroscler Thromb. 2018 Mar 1;25(3):233-243.
-
19. Kakizaki R, Tojo T, Minami Y, Koitabashi T, Woodhams R, Shimohama T, Ishii M, Ako J. Myocardial ischemia induced by major aortopulmonary collateral arteries treated with transcatheter coil embolization. Clin Case Rep. 2017 May 12;5(6):1022-1025.
-
20. Namba S, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Hashikata T, Kitasato L, Hashimoto T, Kameda R, Meguro K, Shimohama T, Tojo T, Ako J. Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels. 2017 Aug;32(8):977-982.
-
21. Nabeta T, Hashikata T, Tojo T, Kakizaki R, Minami Y, Meguro K, Shimohama T, Suzuki S, Inoue Y, Ako J. Localized Inflammation and Aneurysm Formation 10 Years After Sirolimus-Eluting Stent Implantation. Circ J. 2017 Jun 23;81(7):1054-1055.
-
22. Minami Y, Meguro K, Shimohama T, Yanagisawa T, Kakizaki R, Tojo T, Ako J. Successful Retrieval of Entrapped Balloon With Optical Coherence Tomography Guidance. JACC Cardiovasc Interv. 2016 Oct 10;9(19):2070-2071.
-
23. Hashikata T, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, Kitasato L, Hashimoto T, Ishii S, Kameda R, Shimohama T, Tojo T, Ako J. Ezetimibe enhances and stabilizes anticoagulant effect of warfarin. Heart Vessels. 2017 Jan;32(1):47-54.
-
24. Namba S, Yamaoka-Tojo M, Hashikata T, Ikeda Y, Kitasato L, Hashimoto T, Shimohama T, Tojo T, Takahira N, Masuda T, Ako J. Long-term warfarin therapy and biomarkers for osteoporosis and atherosclerosis. BBA Clin. 2015 Aug 12;4:76-80.
-
25. Hashikata T, Yamaoka-Tojo M, Namba S, Kitasato L, Kameda R, Murakami M, Niwano H, Shimohama T, Tojo T, Ako J. Rivaroxaban Inhibits Angiotensin II-Induced Activation in Cultured Mouse Cardiac Fibroblasts Through the Modulation of NF-κB Pathway. Int Heart J. 2015;56(5):544-50.
-
26. Hashikata T, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, Kitasato L, Hashimoto T, Kameda R, Maekawa E, Shimohama T, Tojo T, Ako J. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes. Heart Vessels. 2016 Aug;31(8):1303-10.
-
27. Kitasato L, Shimohama T, Ikeda Y, Namba S, Hashikata T, Kameda R, Sato N, Takeuchi I, Yamaoka-Tojo M, Tojo T, Ako J. Clinical outcomes of chronic kidney disease patients treated with everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES). Biomed Pharmacother. 2015 May;72:6-10.
-
28. Hashikata T, Tojo T, Namba S, Kitasato L, Hashimoto T, Kameda R, Shimohama T, Yamaoka-Tojo M, Takada F, Ako J. Deficiency of creatine kinase in a ST-segment elevation myocardial infarction patient with Kartagener syndrome. Int J Cardiol. 2015 Mar 1;182:31-3.
-
29. Hashikata T, Tojo T, Namba S, Kitasato L, Hashimoto T, Kameda R, Shimohama T, Yamaoka-Tojo M, Ako J. Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months' follow-up: an optical coherence tomography study. Heart Vessels. 2014 Nov 2.
-
30. Kitasato L, Yamaoka-Tojo M, Hashikata T, Ishii S, Kameda R, Shimohama T, Tojo T, Ako J. Factor Xa in Mouse Fibroblasts May Induce Fibrosis More Than Thrombin. Int Heart J. 2014 2014;55(4):357-61.
-
31. Hashikata T, Tojo T, Ishii S, Kitasato L, Kameda R, Shimohama T, Yamaoka-Tojo M, Ako J. Neoatherosclerosis 16 years following bare-metal stent implantation: different tissue components in different underlying lesions observed with optical coherence tomography. Int J Cardiol. 2013 Dec 5;170(1):e8-10.
-
32. Nishinari M, Shimohama T, Tojo T, Shiono T, Shinagawa H, Kameda R, Aoyama N, Izumi T.Two-week interval optical coherence tomography: Imaging evidence on neointimal coverage completion after implantation of the endeavor zotarolimus-eluting stent. Catheter Cardiovasc Interv. 2013 Dec 1;82(7):E871-8.
-
33. Kameda R, Yamaoka-Tojo M, Makino A, Wakaume K, Nemoto S, Kitasato L, Shimohama T, Tojo T, Machida Y, Izumi T. Soluble Fms-like tyrosine kinase 1 is a novel predictor of brain natriuretic peptide elevation. Int Heart J. 2013;54(3):133-9.
-
34. Nishinari M, Aoyama N, Ogawa Z, Yukino S, Oka S, Yano K, Kurosaki Y, Takeuchi I, Imaki R, Tojo T, Shimohama T, Takehana H, Izumi T.Phosphoglucomutase activity as a novel biomarker in patients with acute myocardial infarction. Circ J. 2012 Aug 24;76(9):2197-203.
-
35. Kitasato L, Tojo T, Hatakeyama Y, Kameda R, Hashikata T, Yamaoka-Tojo M. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Cardiovasc Diabetol. 2012 Jun 29;11(1):79.
-
36. Kohro T, Yamazaki T, Izumi T, Daida H, Kurabayashi M, Miyauchi K, Tojo T, Nagai R, on behalf of the JCADII Investigators. Intensively Lowering Both Low-Density Lipoprotein Cholesterol and Blood Pressure Does Not Reduce Cardiovascular Risk in Japanese Coronary Artery Disease Patients. Circ J. 2011;75(9): 2062-70.
-
37. Yamaoka-Tojo M, Tojo T, Wakaume K, Kameda R, Nemoto S, Takahira N, Masuda T, Izumi T. Circulating interleukin-18: A specific biomarker for atherosclerosis-prone patients with metabolic syndrome. Nutr Metab (Lond). 2011 Jan 20;8:3.
-
38. Takeuchi I, Moriguchi M, Imaki R, Fukaya H, Shinagawa H, Shimohama T, Tojo T, Fukuda N, Inomata T, Aoyama N, Soma K, Izumi T. Hemodialysis is an independent predictor of coronary in-stent restenosis after paclitaxel eluting stent implantation. Intern Med. 2010;49(22):2379-84.
-
39. Yamaoka-Tojo M, Tojo T, Takahira N, Masuda T, Izumi T. Ezetimibe and reactive oxygen species. Curr Vasc Pharmacol. 2011 Jan;9(1):109-20.
-
40. Niwano S, Tojo T. Review. Systemic acidosis in acute myocardial ischemia--cause or result of life-threateningventricular arrhythmia? Circ J. 2010;74(9):1794-5. Epub 2010 Aug 10.
-
41. Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, Izumi T. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol. 2010 May 14; 9:17.
-
42. Yamaoka-Tojo M, Tojo T, Kosugi R, Hatakeyama Y, Yoshida Y, Machida Y, Aoyama N, Masuda T, Izumi T. Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis. 2009 Oct 12; 8:41.
-
43. Takeuchi I, Takehana H, Satoh D, Fukaya H, Tamura Y, Nishii M, Shinagawa H, Imai H, Yoshida T, Tojo T, Inomata T, Aoyama N, Soma K, Izumi T. Effect of hypothermia therapy after outpatient cardiac arrest due to ventricular fibrillation. Circ J. 2009 Oct; 73(10):1797-8.
-
44. Yamaoka-Tojo M, Tojo T, Izumi T. Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. Curr Vasc Pharmacol. 2008 Oct;6(4):271-81. Review.
-
45. Yamaoka-Tojo M, Tojo T, Kosugi R, Aoyama N, Niwano S, Kurokawa S, Izumi T. Effect of colestimide on reduction of body weight and waist circumference in metabolic syndrome patients with cardiovascular risk factors. Vasc Disease Prevention. 2008; 5 (3): 183-189.
-
46. Nagai R, Izumi T, Kurabayashi M, Daida H, Tojo T, Hasegawa A, Miyauchi K, Hayashi D, Kohro T, Okada Y, Yamazaki T; JCADII Investigators. Rationale and design of a study to examine lower targets for low-density lipoprotein-cholesterol and blood pressure in coronary artery disease patients. Circ J. 72 (4): 515-520, 2008.
-
47. Yamaoka-Tojo M, Tojo T, Kim HW, Hilenski L, Patrushev NA, Zhang L, Fukai T, Ushio-Fukai M. IQGAP1 mediates VE-cadherin-based cell-cell contacts and VEGF signaling at adherence junctions linked to angiogenesis. Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):1991-7.
-
48. Yamaoka-Tojo M, Tojo T, Shioi T, Masuda T, Inomata T, Izumi T. Central neurotranspeptide, alpha-melanocyte-stimulating hormone (alpha-MSH) is upregulated in patients with congestive heart failure. Intern Med. 2006 Jul;45(7):429-34.
-
49. Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev NA, Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation. 111: 2347-55, 2005.
-
50. Ikeda S, Ushio-Fukai M, Zuo L, Tojo T, Dikalov S, Patrushev NA, Alexander RW. Novel role of ARF6 in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res; 96:467-75, 2005.
-
51. Yamaoka-Tojo M, Ushio-Fukai M, Hilenski L, Chen YE, Tojo T, Fukai T, Fujimoto M, Patrushev NA, Bloom GS, Alexander RW. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species--dependent endothelial migration and proliferation. Circ Res. 95: 276-283, 2004.
-
52. Tsunoda Y, Nakada S, Tojo T, Miyamoto T, Tomoike H. Beneficial effects of CV-11974 on vascular remodeling induced by long-term volume overload in rabbits. Yamagata Med J 2004; 22(1): 29-39.
-
53. Yamaoka-Tojo M, Tojo T, Masuda T, Kitano Y, Machida Y, Kurosawa T, Izumi T. C-reactive protein-induced production of interleukin-18 in human endothelial cells: a mechanism of orchestrating cytokine cascade in acute coronary syndrome. Heart Vessels. 18: 183-187, 2003.
-
54. Yamaoka-Tojo M, Tojo T, Inomata T, Machida Y, Osada K, Izumi T. Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. J Cardiac Failure. 8:21-27, 2002.
-
55. Tojo T, Tsunoda Y, Nakada S, Tomoike H. Effects of long-term treatment with nonselective endothelin receptor antagonist, TAK-044, on remodeling of cardiovascular system with sustained volume overload. J Cardiovasc Pharmacol. 35: 777-85, 2000.
-
56. Fujiwara S, Takeishi Y, Tojo T, Yamaoka M, Nitobe J, Takahashi K, Tomoike H. Fatty acid imaging with 123I-15-(p-iodophenyl)-9-R,S-methylpentadecanoic acid in acute coronary syndrome. J Nucl Med. 40(12): 1999-2006, 1999.
-
57. Fujiwara S, Takeishi Y, Atsumi H, Yamaki M, Takahashi N, Yamaoka M, Tojo T, Tomoike H. Prediction of functional recovery in acute myocardial infarction: comparison between sestamibi reverse redistribution and sestamibi/BMIPP mismatch. J Nuclear Cardiol. 5(2): 119-27, 1998.
